Stockscreener 앱 받기
18.08
0.25%
-0.102
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Marex Group plc Takes $3.67 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Camber Capital Management LP Has $5.60 Million Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Will Denali's Expanding Pipeline Deliver Breakthroughs In Neurodegenerative Medicine? - RTTNews
Wedbush Issues Pessimistic Forecast for Denali Therapeutics (NASDAQ:DNLI) Stock Price - MarketBeat
Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
Denali Therapeutics prices stock offering at $17.50 per share - MSN
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownHere's What Happened - MarketBeat
Denali Therapeutics dips after pricing $200M equity offering - MSN
Denali Therapeutics Prices $200 Million Public Offering - marketscreener.com
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - Sahm
Denali Therapeutics prices $200 million public offering By Investing.com - Investing.com India
Denali Therapeutics prices $200 million public offering - Investing.com
Denali Therapeutics says co prices public offering of 9.14 mln shares at $17.50 each - marketscreener.com
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan
Denali Therapeutics slides after launching $200 million share sale - TradingView — Track All Markets
Denali Therapeutics Plans $200 Million Public Offering - marketscreener.com
Denali Therapeutics announces $200 million public offering By Investing.com - Investing.com Australia
Denali Therapeutics stock falls after announcing $200 million public offering By Investing.com - Investing.com Australia
Denali Therapeutics stock falls after announcing $200 million public offering - Investing.com
Denali Therapeutics announces $200 million public offering - Investing.com
Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option - Stock Titan
Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Technical Reactions to DNLI Trends in Macro Strategies - news.stocktradersdaily.com
Denali enters into a $275M funding deal with Royalty Pharma - MSN
Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy - Indian Pharma Post
Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance
Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance
BTIG Research Reiterates Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
3,947,387 Shares in Denali Therapeutics Inc. $DNLI Acquired by Norges Bank - MarketBeat
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch By Investing.com - Investing.com South Africa
Denali Therapeutics (MUN:4DN) Price Target Decreased by 15.88% to 28.11 - Nasdaq
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch - Investing.com Nigeria
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating - marketscreener.com
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals - BioSpace
BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation - Nasdaq
William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating - 富途牛牛
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Transcript : Denali Therapeutics Inc.Analyst/Investor Day - MarketScreener
Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement - marketscreener.com
Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement - TradingView
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
Denali Therapeutics secures $275M royalty funding deal - MSN
Denali Therapeutics Secures $275M Royalty Funding Deal - TipRanks
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start - Sahm
0.56%
1.23%
자본화:
|
볼륨(24시간):